The present invention relates to a method for converting at least one oligo- and/or polysaccharide into fructose comprising the steps of: a) adding to a composition comprising water, phosphate and at least one oligo- and/or polysaccharide at least four enzymes, and b) subsequently enzymatically converting the at least one oligo- and/or polysaccharide to fructose in the presence of the at least four enzymes, wherein in step a) at least one additional saccharide is added, whereby the at least one additional saccharide is selected from the group consisting of saccharides comprising 20 or less monosaccharide residues and/or combinations thereof; wherein in step a) the at least four enzymes, preferably at least five enzymes, are selected from the group consisting of transferases, phosphorylases, mutases, isomerases, hydrolases, phosphatases and combinations thereof; and wherein at least one enzyme in step a) is a phosphatase.

The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.

Fermented milk, containing 0.8 g or more of dephosphorylated casein per 100 g of the fermented milk. Dephosphorylated milk, containing dephosphorylated casein. A method for manufacturing fermented milk, including: (a) fermenting raw material milk in a presence of a protein phosphatase and (b) fermenting raw material milk enzyme-treated with the protein phosphatase.

Provided herein are methods, compositions, and non-naturally occurring microbial organism for preparing compounds such as α-butanol, butyric acid, succinic acid, 1,4-butanediol, 1-pentanol, pentanoic acid, glutaric acid, 1,5-pentanediol, 1-hexanol, hexanoic acid, adipic acid, 1,6-hexanediol, 6-hydroxy hexanoic acid, ε-Caprolactone, 6-amino-hexanoic acid, ε-Caprolactam, hexamethylenediamine, linear fatty acids and linear fatty alcohols that are between 7-25 carbons long, linear alkanes and linear α-alkenes that are between 6-24 carbons long, sebacic acid and dodecanedioic acid comprising: a) converting a C.sub.N aldehyde and pyruvate to a C.sub.N+3 β-hydroxyketone intermediate through an aldol addition; and b) converting the C.sub.N+3 β-hydroxyketone intermediate to the compounds through enzymatic steps, or a combination of enzymatic and chemical steps.

Various examples according to the present disclosure provide a fermentation method. The fermentation method includes producing at least about 10 g/L of a bioproduct and one or more heterologous polypeptides by fermenting a medium using an engineered microorganism. About 2 wt % to about 100 wt % of the one or more heterologous polypeptides are encapsulated intercellularly in the engineered microorganism. The method further includes isolating the engineered microorganism including the encapsulated one or more heterologous polypeptides. About 50 wt % to about 100 wt % of the one or more heterologous polypeptides retain functionality following isolation of the engineered microorganism.

The present disclosure relates to methods for using one or more polypeptides with phytase activity in grain processing, ethanol, and biofuel production.

Methods, compositions, and systems for propagation and fermentation, particularly large scale operations for production of ethanol and dried distiller's grain are provided. Addition of Z. mobilis to propagation and/or fermentation decreases lactic acid bacterial contamination.

Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: acid reflux disease, stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy. The formulation is also for treating or reducing intolerance of gluten, corn or soy.

The present application relates to a steam treated pelletized feed composition comprising a granule comprising a core and a coating wherein the core comprises an active compound and the coating comprises a salt.

This disclosure is directed to methods of formulating a customized animal feed that includes a customized enzyme composition. Methods of achieving one or more zootechnical objectives for an animal are also provided.